Iovance Biotherapeutics (IOVA) Misses Q1 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. DOX
4. AMGN
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to Iovance Biotherapeutics (IOVA) Misses Q1 EPS by 4c

Iovance Biotherapeutics Reports First Quarter 2020 Financial Results and Provides a Corporate Update

May 5, 2020 4:02 PM EDT

SAN CARLOS, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL and peripheral-blood lymphocyte, PBL), today reported first quarter 2020 financial results and provided a corporate update.

We continue making strong progress toward commercializing Iovance TIL for melanoma and cervical cancer indications, said Maria Fardis, Ph.D., MBA, Iovance President and Chief Executive Officer. While COVID-19 has impacted healthcare systems globally, we have been able to continue our key business operations due to dedication from our employees and... More